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TUMOUR necrosis factor-ex (TNF-ex) has been implicated as
an important inflammatory mediator. In vitro, TNF-t is
reported to activate human polymorphonuclear neutro-
phils (PMN), inducing responses such as phagocytic ac-
tivity, degranulation and oxidative metabolism. Biological
responses to TNF-t are initiated by its binding to specific
cell surface receptors, and various studies have shown that
the major TNF receptor species on PMN is the 75 kDa
receptor. To verify the suggestion that the receptor bind-
ing domain includes the region close to the N-terminus
of the TNF-t molecule, four TNF-t derivatives termed
muteins were constructed, using a synthetic cDNA frag-
ment substituting the N-terminal 3-7 selected hydrophilic
or hydrophobic amino acids in the original TNF-t gen-
omic DNA. Binding of muteins to PMN was assessed
using monoclonal antibodies recognizing either the
55 kDa (p55) or the 75 kDa (p75) TNF receptor subtypes.
Blocking by muteins of anti-p75 antibody binding toPMN
was as expected from their N-terminal amino acid
composition and hydrophilic properties. Hydrophilic
muteins competed well with anti-TNF receptor antibodies
for binding to the p75 receptor. In contrast, hydrophobic
muteins were unable to block anti-p75 binding. Similarly,
degranulation, chemiluminescence or enhancement of the
PMN response to specific stimuli by the muteins
correlated with the hydrophilic properties of the muteins.
The significance of these observations in relation to the
molecular structure of TNF-x is discussed.
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Introduction
The multifunctional cytokine tumour necrosis
factor-0 (TNF-00 plays a role in the regulation of
many biological responses in vivo, and has been
implicated in a wide range of pathological
conditions, including the host response to Gram-
negative sepsis, cachexia and the acute phase
response to infection and trauma. During the
course of an inflammatory response, TNF-0c is
released by monocytes, macrophages, T-lympho-
cytes and polymorphonuclear neutrophils (PMN).
In vitro, TNF-0 exerts a wide range of effects on
target cells. 2’3 The first step in the induction of these
various cellular responses is the binding of TNF-0c
to specific cell surface receptors. Two such
receptors, binding both TNF-0 and TNF-fl, have
recently been cloned by a number of groups, and
the availability of specific monoclonal antibodies to
these receptors has allowed the investigation of
their distribution and regulation.
4-9 These distinct
receptors, termed p55 and p75, are expressed in
various amounts on different cell lines. 1’11
The activation of PMN by TNF-0 is a critical
component of the inflammatory response, and
(C) 1993 Rapid Communications of Oxford Ltd
in vitro TNF-x has been shown to enhance phago-
cytosis, oxidative metabolism and aggregation of
PMN, as well as increasing cell surface expression of
integrin molecules (CD11/CD18) and hence pro-
moting adherence of PMN to vascular en-
dothelial cells and transendothelial migration.
12<s
The existence on PMN of high aflqnity receptors for
TNF-0 has been demonstrated in several studies.6’7
Based on their susceptibility to inhibition of TNF-0
binding by anti-p55 and anti-p75 monoclonal
antibodies, PMN are believed to display similar
amounts of the two TNF receptor sub-types on
their surface. 5’18’9 However, a study from the
authors’ laboratory demonstrated binding to PMN
of anti-p75 TNF receptor monoclonal antibody
alone, as measured by flow cytometry.
2 It was
observed that binding of this antibody to PMN was
markedly decreased by treatment of PMN with
activating agents such as granulocyte macrophage
colony-stimulating factor and formyl-methionyl-
leucyl-phenylalanine, though not with interferon-y,
the tumour promoting phorbol ester PMA or
calcium ionophore A23187.
The TNF-0 domain responsible for receptor
binding has been shown to be located in the
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N-terminal portion of the molecule,21’22 but the
exact structure responsible for binding has not been
precisely defined. For this purpose, four TNF-0
derivatives termed ’muteins’ were produced, in
which 3-7 amino acids of native TNF-0 have been
replaced, using synthetic cDNA expressed in
Escherichia coli. The authors have previously
demonstrated differential binding of these muteins
to Jijoye Burkitt lymphoma cells, which express
only the p75 TNF receptor, and to the human
epithelioid carcinoma HeLa cell line, which
expresses the p55 receptor alone, suggesting that
N-terminal amino acids play an important role in
the binding of TNF-0 to its cell surface receptors.
23
In the present study the ability of these muteins to
prevent binding of anti-TNF receptor antibodies to
PMN was examined. Additionally, the activation of
PMN by muteins and native TNF- was compared,
and we report that the activities of the muteins on
PMN correlate with their N-terminal amino acid
composition and hydrophilic properties. These
findings emphasize the importance of the N-
terminus of the TNF-0 molecule in binding to
the p75 TNF receptor on PMN.
Materials and Methods
Materials: Muteins III, IV, V and VI (for details of
structures see Results) were constructed in the
Department of Bioorganic Chemistry, Polish
Academy of Sciences, Lodz, Poland, using synthetic
oligonucleotides to induce changes in the cDNA
encoding the 7 N-terminal amino acids of native
WNP-0.24 The cDNA was expressed in E. coli, and
resulting muteins were purified by ion exchange
chromatography. Amino acid sequences were
analysed by automated Edman degradation using
an Applied Biosystems ABI 477A protein se-
quencer. Mutein IV molecules formed inclusion
bodies when expressed in E. coli, which were
solubilized with 6 M guanidine HC1, and purified by
phenyl Sepharose chromatography, before submis-
sion to sequence analysis. Endotoxin contamination
amounted to approximately 1.9 ng endotoxin per
mg protein, as estimated using a commercially
available assay (Sigma Chemical Co., St Louis, MI,
USA).
Recombinant human TNF- (specific activity
5 x 10v U/mg) was supplied by Genentech Cor-
poration (San Francisco, CA, USA) and by the
Department of Bioorganic Chemistry, Lodz,
Poland. Zymosan A, luminol, formyl-methionyl-
leucyl-phenylalanine (fMLP) and Triton-X 100
were purchased from Serva (Feinbiochimica GmbH
and Co., Heidelberg, Germany) and from Sigma
Chemical Co. (St Louis, MI, USA). Biotinylated
goat anti-mouse IgG and streptavidin-phyco-
erythrin were from Southern Biotechnology
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(Birmingham, AL, USA). The monoclonal anti-
bodies used to detect the p55 (Htr-9) and the p75
(Utr-1) TNF receptors were kindly provided by Dr
Manfred Brockhaus (Roche, Basel, Switzerland),
and OX-20 (mouse and anti-rat IgG1), which
served as a control antibody, was kindly provided
by Dr Don Mason (Oxford, UK). Gradisol G was
obtained from Polfa (Kutno, Poland). Medium
RPMI-1640, Hank’s buffered salt solution (HBSS),
phosphate buffered saline (PBS) and foetal calf
serum (FCS) were all purchased from Gibco
Laboratories (Paisley, UK). Normal human serum
was prepared from blood collected from laboratory
personnel.
Preparation of peripheral blood neutrophils: Whole blood
anticoagulated with 10 U/ml heparin was obtained
from healthy adult volunteers. PMN were isolated
by a previously described method,
25 using rapid
one-step centrifugation with Gradisol G (1.115 g/
cm3, 440 mOsm/kg H.O). Ceils from interphase
were washed once in PBS, and resuspended in
HBSS at a concentration of 5 x 106/ml. The
neutrophils obtained were > 96% pure and viability
was greater than 98%, as determined by Trypan
blue exclusion.
Immunofluorescence studies: PMN (0.5 106/ml) were
suspended in HBSS supplemented with 10% (v/v)
normal human serum and incubated for 15 min at
4C. The serum blocks cell surface Fc receptors, and
hereby eliminates non-specific Fc-dependent bind-
ing. The PMN were incubated with either TNF-0
or muteins, at a concentration of 100 ng/ml, for
30 min at room temperature, washed with PBS
supplemented with 3% bovine serum albumin and
0.02% sodium azide, and incubated with optimal
concentrations (10/g/ml) of anti-TNF receptor
monoclonal antibodies for a further 30 min at 4C.
In the initial set of experiments anti-TNF receptor
monoclonal antibodies Utr-1 and Htr-9, which
recognize p75 and p55 TNF receptors respec-
tively,
p6 were used. However, because only the p75
TNF receptor was visualized by flow cytometry on
both resting and stimulated PMN, subsequent
analyses were performed using monoclonal anti-
body Utr-1 only. PMN were then washed again,
and incubated with 1:100 dilution (1/.zg/ml) of
biotinylated goat anti-mouse IgG, followed by
1:100 dilution (1/zg/ml) of streptavidin conjugated
to phycoerythrin, both for 30 min at 4C. The cells
were washed twice more and analysed immediately
using a FACStar flow cytometer (Becton Dick-
inson, CA, USA). TNF receptors were analysed on
viable ceils by gating on forward (FSC) and side
scatter (SSC). The results were analysed using the
Becton Dickinson LYSYS data analysis software
package, and data are presented in the form of
FACS profiles.TNF receptors on neutrophils
Measurement ofenu,yme secretion: PMN were resuspended
in PBS at a concentration of 2 106/ml. In some
experiments PMN were pretreated with 5/g/ml
cytochalasin B for 15 min at 37C before use. The
appropriate concentrations of either TNF-0 or
muteins were then added for a further 45 min at
37C. Released enzyme activities were measured in
cell-free supernatants. The activity of fl-glucur-
onidase was evaluated using 0.01 M phenolphtha-
lein glucuronate as a substrate.
27 Lysozyme activity
was measured by a turbidometric method,
28 using
egg-white lysozyme as a standard. Release of lactate
dehydrogenase (LDH) from PMN was determined
spectrophotometrically, using a commercially avail-
able assay from Sigma Chemical Co. (St Louis, MI,
USA). This assay is based on the characteristic light
absorption at 340 nm by diphosphopyridine nucleo-
tide hydrogenase reduced coenzyme. All tested
substances were diluted in PBS, which also served
as a control for spontaneous degranulation ofPMN.
The enzyme activities released into the neutrophil
supernatants were expressed as a percentage of the
total activity released from PMN by treatment with
0.2% Triton-X 100.
Chemiluminescence studies: PMN were incubated for
30 min at room temperature in the presence of
either TNF-0 or muteins (1-100 ng/ml). Alterna-
tively, PMN were pre-incubated for 30 min at room
temperature in the presence of either TNF-0 or
muteins (1-100 ng/ml), before addition of fMLP
(10
-6 M)). For the measurement of chemilumin-
escence (CL) generation, each sample contained
350/1 cells (3.5 105), 20/1 luminol solution and
10/1 of either TNF-0 or mutein. PBS was added
to give a final volume of 1.0 ml.
29 CL generation
was evaluated using a Luminometer 1251 (BioOrbit
Turku, Finland) coupled to an IBM-PC At
computer. This allowed the simultaneous examina-
tion of 25 samples. Investigations were carried out
at 37C and each measurement was made on three
different PMN samples in triplicate.
Results
Structure of TNF- muteins: The N-terminal amino
acids in the muteins, as compared to native TNF-,
are as follows"
Native TNF-0 Met-Val-Arg-Ser-Ser-Ser-Arg-Thr- (hydrophilic)
Mutein III Met-Lys-His-Lys-Arg-His-Arg-His- (hydrophilic)
Mutein IV Met-Phe-Met-Ala-Phe-Phe-Met-Met- (hydrophobic)
Mutein V Met-Val-Arg-Ser-Ser-Ile-Val-Ile- (hydrophilic)
Mutein VI Met-Arg-Ile-Arg-Met- (hydrophobic)
The hydrophobic and hydrophilic character of
the muteins was evaluated according to the
generally accepted algorithm.
3 The hydrophilic
properties of mutein V were thus calculated to be
slightly lower than those of either mutein III or
native TNF-a.
Immunojquorescence staining of PMN for TNF receptors:
This study confirmed the authors’ earlier observa-
tions that PMN do not bind the anti-p55 TNF
receptor monoclonal antibody Htr-9, as measured
on a Becton Dickinson FACStar flow cytometer. In
contrast, significant staining of PMN with mono-
clonal antibody Utr-1, specific for the p75 TNF
receptor (Figure 1) was obtained. Pretreatment of
PMN with human recombinant TNF-0 (100 ng/ml)
for 30 min completely abolished binding of Utr-1
to PMN, indicating that this monoclonal antibody
binds to a surface site specific for TNF-0 (Figure
2). Binding of Utr-1 was also blocked by similar
pretreatment of PMN with mutein III, and to a
lesser extent following pre-incubation ofPMN with
mutein V. However, treatment of PMN with
muteins IV and V1 had no significant effect on
anti-p75 antibody binding (Figure 2).
Chemiluminescence activity: Treatment of human PMN
with TNF-0 results in the production of increased
amounts of superoxide anions in response to a
subsequent challenge with fMLP, reflecting release
of myeloperoxidase from neutrophil azurophil
granules, which can be measured as luminol
enhanced chemiluminescence. From Figure 3, it is
clear that when added alone, TNF-0 and muteins
III and V slightly stimulated superoxide generation
by PMN, whereas muteins IV and V1 possess only
negligible PMN stimulatory activity. In contrast,
treatment of PMN with fMLP (10
-6 M) induced
significant generation of chemiluminescence, which
was markedly enhanced by pre-incubation of PMN
with either TNF-, mutein III or mutein V prior
FL2
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FIG. 1. Flow cytometric analysis of unstimulated human PMN stained
with 10#g/ml of monoclonal anti-TNF receptor antibodies Utr-1 and
Htr-9, or with irrelevant control antibody OX-20. PM N bind anti-p75 TNF
receptor antibody only.
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FIG. 2. Flow cytometric analysis of the binding of monoclonal antibodies Utr-1 and OX-20 to human PMN pretreated with TNF-e (1 O0 ng/ml)
or muteins III-VI (100 ng/ml) for 30 min at room temperature. TNF-e, mutein III and to a lesser extent mutein V block binding of Utr-1 to PMN.
to addition of fMLP (Figure 4). Pretreatment of
PMN with muteins IV and VI failed to enhance
fMLP-induced chemiluminescence generation
(Figure 4).
Release of lysosomal enwmes from PMN: Activation of
freshly isolated PMN by a number of agents leads
to the release of lysosomal enzymes from neutrophil
granules. We have measured the release of two such
enzymes--lysozyme and fl-glucuronidase--from
PMN stimulated with either TNF<z, muteins or
fMLP.
Addition of TNF-, mutein III and mutein V, as
well as fMLP, resulted in release of comparable
amounts of lysozyme (Table 1). In contrast, muteins
IV and VI did not display any activity in this
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FIG. 3. Chemiluminescence of human PMN stimulated with for 30 min at room temperature with either (A) TNF-a, (B) mutein III, (C) mutein IV, (D)
mutein V, (E) mutein VI. CL generation was measured using a Luminometer 1251. TNF-a, mutein III and mutein V, but not muteins IV and VI, stimulate
chemiluminescence of human PMN. [-]-- Control, --+-- ng/ml, --@-- 10ng/ml, --A-- 100ng/ml.
system. We have also investigated degranulation of
PMN after treatment with cytochalasin B, which
affects cytoskeletal proteins. As expected, cytochala-
sin greatly enhanced fMLP-induced degranulation
(Table 1), but was without effect on release of
lysozyme in response to either TNF-z or muteins
III and V. Interestingly, following cytochalasin B
treatment, mutein IV also increased lysozyme
release to levels comparable to those observed with
the other muteins.
Table 2 shows the results of measurements of
fl-glucuronidase activity in cell-free extracts. In the
absence of cytochalasin B, only fMLP and TNF-z
promoted significant release of fl-glucuronidase.
Addition of cytochalasin B resulted in increased
fl-glucuronidase activity in supernatants from PMN
stimulated with fMLP, TNF-0c and mutein III.
There was no significant effect on fl-glucuronidase
activity in supernatants from PMN challenged with
muteins IV, V and VI. Statistical analysis of the
data revealed that only fMLP-induced release was
significantly (p < 0.05) above background release.
Discussion
TNF-0c is released during the course of
inflammatory reactions by several cell types, chiefly
monocytes, but also by PMN,
31 and it participates
in the host response to infection and trauma.
Moreover TNF-z may cause tissue damage by
augmenting PMN function, both by directly
activating neutrophils and by affecting their
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FIG. 4. Chemiluminescence of human PMN in response to fMLP (10-e M) followincj pretreatrnent for 30 rnin at room temperature with either (A)
TNF-, (13) rnutein III, (C) rnutein IV, (D) rnutein V, (E) rnutein VI. CL cjeneration was measured usincj a Lurninorneter 1251. TNF-, rnutein III and
rnutein V enhance chemiluminescence in response to fMLP. []-- Control, / ncj/rnl, 10 ncj/rnl, --
100 ncj/rnl.
Table 1. Lysozyme release from PMN exposed to TNF- and
muteins
Table 2. fl-Glucuronidase release from PMN exposed to TNF-
or muteins
Addition Conc. Control Cytochalasinb Addition Conc. Control Cytochalasin
PBS 2.3 _+ 0.9 2.3 _+ 1.0 PBS 3.1 _+ 1.4 2.9 _+ 1.5
fMLP (10
-7 M) 25.9 _+ 4.4* 65.7 _+ 4.1" fMLP (10
-7 M) 8.1 _+ 3.1" 16.6 _+ 1.5"
TNF- (10 ng/ml) 19.7 _+ 8.6* 21.9 _+ 1.1" TNF- (10 ng/ml) 8.1 _+ 3.6* 11.0 _+ 5.9
Mutein III (10 ng/ml) 21.8 _+ 7.8* 26.8 _+ 2.3* Mutein III (10 ng/ml) 3.4 _+ 2.9* 14.9 +_ 8.5
Mutein IV (10 ng/ml) 4.4 _+ 4.1 12.8 _+ 1.9" Mutein IV (10 ng/ml) 4.4 +_ 4.1 7.7 +_ 6.7
Mutien V (10 ng/ml) 17.1 _+ 1.4" 14.1 _+ 1.7" Mutein V (10 ng/ml) 5.7 _+ 5.0 9.5 _
6.6
Mutien VI (10 ng/ml) 4.6 _+ 4.4* 4.8 _+ 3.9 Mutein VI (10 ng/ml) 4.8 _
4.2 6.4 _+ 5.3
Enzyme activity (_+SD, n 4) in the supernatant was ex-
pressed as a percentage of total activity released by 0.2%
Triton-X 100. LDH activity was less than 5% of the amount
measured in a solution obtained by cell pellet lysis.
b PMN (2 x 106) were treated with cytochalasin B (5 /g/ml)
for 15 min at 37C, before addition of TNF- or muteins.
Statistically significant (p_< 0.05) difference relative to re-
sponse in the presence of PBS alone determined by Student’s
t-test.
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Enzyme activity (__+SD, n 4) in the supernatant was ex-
pressed as a percentage of total activity released by 0.2%
Triton-X 100. LDH activity was less than 5% of the amount
measured in a solution obtained by cell pellet lysis.
b PMN (2 x 106) were treated with cytochalasin B (5 /g/ml)
for 15 min at 37C, before addition of TNF- or muteins.
Statistically significant (p < 0.05) difference relative to re-
sponse in the presence of PBS alone determined by Student’s
t-test.TNF receptors on neutrophils
responses to other stimuli such as fMLP. For
example, TNF<z enhances phagocytosis, oxidative
metabolism, aggregation, degranulation and adher-
ence of PMN following binding to its specific cell
surface receptors.
12-15 Its effects on PMN function
can be completely blocked by anti-TNF-0 anti-
bodies and TNF-z inhibitors. 32’33
In the present study, the effects of TNF-0
derivatives termed muteins, which differ from
native TNF-0 in their amino acid composition, on
human PMN were investigated in order to examine
the structural requirements of TNF- for binding
to PMN receptors. Since antibodies recognizing the
N-terminus of TNF-z block its attachment to
cellular receptors and inhibit biological effects of
TNF-021’22 we have replaced the 3--7 N-terminal
amino acids of TNF-0, yielding four muteins with
hydrophobic/hydrophilic characteristics different to
those of the native molecule. The results confirm
earlier observations2 that human PMN appear to
express predominantly the 75 kDa TNF receptor
type, as shown by the flow cytometric analysis of
the binding of monoclonal antibodies against the
p75 TNF receptor. In contrast, there was no
detectable binding of anti-p55 TNF receptor
antibodies to PMN. Binding to p75 was abolished
by addition of TNF-0, and muteins III and V, but
not muteins IV and VI. In an earlier study the
authors compared the ability of TNF-0 and muteins
to compete with anti-TNF receptor antibodies for
binding to Jijoye Burkitt lymphoma cells and to the
human epithelioid carcinoma HeLa cell line, which
selectively express either p75 or p55 receptors alone.
The authors demonstrated that TNF-0, mutein III
and mutein V bind to HeLa cells, whereas only
TNF-0 and mutein III competed with anti-p75
antibodies for binding to the p75 receptor on Jijoye
cells. Muteins IV and VI failed to recognize either
TNF receptor species.
23 The ability of mutein III,
therefore, to prevent anti-p75 monoclonal antibody
binding to PMN further supports the observations
that the surface receptor on PMN for TNF-0 is
primarily the 75 kDa sub-type. This is also
corroborated by the data showing enhancement by
mutein III of superoxide anion production by PMN
in response to fMLP. Finally, mutein III, like native
TNF-0 itself, induces release of lysozyme from
PMN, presumably as a result of binding to the p75
receptor. Secretion of fl-glucuronidase in response
to mutein III was only observed following
cytochalasin B treatment of PMN, although this
release was not apparently significantly above
background levels.
Since mutein V did not affect binding of anti-p75
to Jijoye cells,
2 its activity in inhibiting anti-p75
receptor binding to PMN appears inconsistent with
the preponderance of p75 on PMN. It is possible
that this mutein binds to a different epitope on
Jijoye p75 to that recognized by Utr-1, and thus
appears not to affect binding of this antibody to
Jijoye cells. Mutein V also induced neutrophil
responses comparable to those elicited by TNF-0
and mutein III, despite the apparent absence of p55
on PMN. However, Porteu and colleagues
18 clearly
demonstrated inhibition by anti-p55 antibody Htr-9
of 125I-TNF-0 binding to PMN, suggesting that p55
receptors are indeed present on these cells. It was
also reported by the same group that activated
human PMN release soluble fragments of both
TNF receptors. This shedding of cell surface
receptors occurs by at least two distinct mechan-
isms. Exposure of PMN to sonicated neutrophil
azurophil granules results in almost exclusive
release of a fragment of the p75 TNF receptor, by
an elastase dependent mechanism. In contrast,
stimulation of PMN by fMLP leads to shedding of
similar amounts of both p55 and p75, and is
insensitive to elastase inhibitors.
8 It is therefore
clear that p55 is indeed expressed on the surface of
human PMN. In the flow cytometric studies, it is
possible that although binding of anti-p55 anti-
bodies to PMN was not detectable, low levels of
p55 are sufficient to allow binding to this receptor
and hence initiation of neutrophil responses by
mutein V.
Muteins IV and VI did not compete with
anti-TNF receptor antibodies for binding to PMN,
which is in accordance with their lack of ability to
block binding of Utr-1 and Htr-9 to Jijoye and
HeLa cells.
23 In addition, these compounds did not
induce superoxide anion production, either alone,
or in combination with fMLP, and were without
effect on secretion of fl-glucuronidase. Lysozyme
release from PMN in the absence of cytochalasin B
was also unaltered, although in the presence of
cytochalasin B mutein IV induced significant release
of this enzyme into the cell supernatant. The
mechanism responsible for this effect is at present
unclear.
The results presented in this report confirm that
N-terminal amino acids are critical for both binding
to neutrophils and induction of PMN responses by
TNF-. This is in agreement with previously
published data showing that changes in the basicity
of N-terminal amino acids affect the cytotoxic
activity of TNF-0,
34 as well as with our own
findings of differential binding of muteins to HeLa
and Jijoye cells.
2 The question of structure-func-
tion relationships to TNF-0 activity has also been
addressed by other investigators.
s-37 For example,
a histidine residue at position 15 of TNF<z was
found to be an essential requirement for cytotoxic
activity,
3s whereas in another study chemical
modifications of N-terminal amino groups revealed
a strong correlation between the extent of
modification and biological activity.
6 Details in this
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report also describe that the two muteins with
hydrophilic N-terminal portions similar to those of
native TNF-0 are effective in inducing neutrophil
responses by binding to cell surface receptors. In
contrast, hydrophobic muteins IV and V1 failed to
activate neutrophils in our system. In summary, it
appears that recognition of receptors on PMN and
induction of cellular responses by TNF-0 is
governed at least in part by the nature of the
N-terminal amino acids and the hydrophilic
properties of this pleiotropic cytokine.
References
1. Sherry B, Cerami A. Cachectin/tumour necrosis factor exerts endocrine,
paracrine and autocrine control of inflammatory responses. J Cell Biol 1988
107: 1269-1277.
2. Ziegler EJ. Tumour necrosis factor in humans. New Engl J Med 1988; 318:
1533-1535.
3. Beutler B, Cerami A. Cachetin: than tumour necrosis factor. New
Engl J Med 1990; 316: 379-385.
4. Hohmann HP, Remy R, Brockhaus M, Loon AP. Two different cell
types have different major receptors for human tumour necrosis factor. J Biol
Chem 1989 264: 14927-14934.
5. Brockhaus M, Schoenfeld HJ, Schlager EJ, Hunziker W, Lesslauer W,
Loetscher H. Identification of two types of tumour necrosis factor receptors
human cell lines by monoclonal antibodies. Proc Natl A cad Sci USA
1990; 8"/: 312%3131.
6. Gray PW, Barrett K, Chantry DH, Turner M, Feldmann M. Cloning of
human tumour necrosis factor (TNF) receptor cDNA and expression of
recombinant soluble TNF-binding protein. Proc NatlA cad Sci USA 1990;
87: 7380-7384.
7. Schall TJ, Lewis M, Koller KJ, et al. Molecular cloning of receptor for
human tumour necrosis factor. Cell 1990; 61: 361-370.
8. Smith CA, Davis T, Anderson D, eta]. A receptor for tumour necrosis factor
defines unusual family of cellular and viral proteins. Science 1990; 248:
1019-1023.
9. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R. Characteriza-
tion of binding and biological effects of monoclonal antibodies against
human tumour necrosis factor receptor. J Exp Med 1990; 171: 415-426.
10. Ryffel B, Brockhaus M, Greiner B, Mihatsch MJ, Gudat BM. Tumour
necrosis factor distribution in human lymphoid tissue. Immunology 1991; 74:
446-452.
11. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA, Goeddel
DV. The two different receptors for turnout necrosis factor mediate distinct
cellular responses. Proc NatlAcad Sci USA 1991; 88: 9292-9296.
12. Larrick JW, Graham D, Toy K, Lin LS, Senyk G, Fendly BM. Recombinant
tumour necrosis factor activation of human granulocytes. Blood 1987;
69: 640-644.
13. Steinbeck MJ, Roth JA. Neutrophil activation by recombinant cytokines.
Rev Infect Dis 1989; 11 549-568.
14. Arnaout MA. Leukocyte adhesion molecule deficiency: its structural basis,
pathophysiology and implications for modulating the inflammatory response.
Immuno! Rev 1990; 114: 146-180.
15. Limb GA, Hamblin AS, Wolstencroft RA, Dumonde DC. Selective upregu-
lation of human granulocyte integrins and complement receptor by
cytokines. Immunology 1991; 74: 696-702.
16. Shalaby MR, Palladino MA, Hirabayashi SE, et al. Receptor binding and
activation of polymorphonuclear neutrophils by tumour necrosis factor-0.
J Leukocyte Bio! 1987; 41 196-204.
17. Pichyangkul S, Schick D, ia F, Berent S, Bollon A, Kahn A. Binding of
tumour necrosis factor-alpha (TNF-) to high-affinity receptors poly-
morphonuclear cells. Exp Hematol 1987; 15: 1055-1059.
18. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan C. Human
neutrophil elastase releases ligand-binding fragment from the 75-kDa
tumour necrosis factor (TNF) receptor. J Biol Chem 1991 266: 18846-18853.
19. Porteu F, Nathan C. Shedding of tumour necrosis factor receptors by
activated human neutrophils. J Exp Med 1990; 172: 599-607.
20. Zeman K, Tchorzewski H, Paleolog E, Brennan F, Feldmann M. Identifica-
tion of TNF receptors human polymorphonuclear neutrophils by
clonal antibodies. 1992; Submitted for publication.
21. Socher SH, Riemen MW, Martinez D, et al. Antibodies against amino acids
1-15 of tumour necrosis factor block its binding to cell-surface receptor.
Proc NatlA cad Sci USA 1987; 84: 8829-8833.
22. Goh CR, Porter AG. Structural and functional domains in human tumour
necrosis factors. Protein Eng 1991; 4: 386-389.
23.’ Tchorzewski H, Zeman K, Paleolog E, eta]. The effects of tumour necrosis
factor (TNF) derivatives TNF receptors. 1992; Submitted for publication.
24. Klysik J, Konarzewska-Zglinska A, Galazka G, et al. Synthesis and expres-
sion in E. coli of the gene for tumor necrosis factor. Arch Immunol Therap
Exp 1992; 39: 349-354.
25. Zeman K, Tchorzewski H, Majewska E, Pokoca L, Pinkowski R. A simple
and rapid method for simultaneous purification of peripheral blood lympho-
cytes and granulocytes. Immunol Pol 1988; 13: 217-224.
26. Cope AP, Aderka D, Doherty M, et al. Soluble tumour necrosis factor (TNF)
receptors increased in the and synovial fluids of patients with
rheumatic diseases. Arthritis Rheum 1992; 35: 1100-1109.
27. Ghebrehiwet B. The release of lysosomal enzymes from human polymorpho-
nuclear leukocytes by human C3a. Clin Immunol Immunpathol 1984; 30:
321-329.
28. Wright DG. Human neutrophil degranulation. Methods Engymol 1988; 162:
538-551.
29. Kantorski J, Tchorzewski H. The effects of serine and thiol inhibitors
the chemiluminescence of human neutrophils in investigations in vitro.
J Biolum Chemilum 1992; 7: 37-45.
30. Kyte J, Doolittle RF. A simple method for displaying the hydrophobic
character of protein. J Mol Biol 1982; 157: 105-132.
31. Dubravec DB, Spriggs DR, Mannick JA, Rodrick ML. Circulating human
peripheral blood granulocytes synthesise and secrete tumour necrosis factor- . Proc Natl Acad Sd USA 1990; 87: 6758-6761.
32. Ferrante A, Hauptmann B, Seckinger P, Dayer JP. Inhibition of tumour
necrosis factor alpha (TNF-0t)-induced neutrophil respiratory burst by TNF
inhibitor. Immunology 1991; 72: 440-442.
33. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol 1992; 62:
S3-S10.
34. Soma GI, Kitahara N, Tsuji Y, et al. Improvement of cytotoxicity of tumour
necrosis factor (TNF) by increase in the basicity of its N-terminal region.
Biochem Biophys Res Commun 1987; 148: 629-635.
35. Yamamoto R, Wang A, Vitt CR, Lin LS. Histidine-15: important role in
the cytotoxic activity of human turnout necrosis factor. Protein Eng 1989; 2:
553-558.
36. Utsuni T, Hung MC, Klostergaard J. The role of amino functions in
recombinant human tumour necrosis factor in expression of biological
activity. Molec Immunol 1992; 29: 77-81.
37. Yamagushi J, Kawashima H, Matsuo N. Mutational analysis of structure-
activity relationships in human tumor necrosis factor-alpha. Protein Eng
1990; 3: 713-719.
ACKNOWLEDGEMENTS. This work supported by grant No. 40209101
from the Committee for Research and Science, Poland, and from the Polish
Science Foundation, by the Arthritis and Rheumatism Council and British Heart
Foundation (EMP), and by British Council Academic Link Agreement. The
authors thank Prof. W. Stec for providing recombinant human TNF-.
Received 10 November 1992"
accepted 1 December 1992
48 Mediators of Inflammation. Vol 2.1993